Previous 10 | Next 10 |
Theravance Biopharma press release ( NASDAQ: TBPH ): Q4 GAAP EPS of -$0.15 beats by $0.02 . Revenue of $14.6M (-2.3% Y/Y) misses by $1.13M . Discontinuing investments in research, reducing headcount by approximately 17%. Increases capital return program to $325 mil...
Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update PR Newswire Increases capital return program to $325 million from $250 million ; as of 2/27/23, approximately $170 million rem...
Irenic Capital Management, which owns ~4.2% of the outstanding shares of Theravance Biopharma ( NASDAQ: TBPH ), is calling on the company's board to undertake a strategic review, among other measures. Irenic is also asking for a cut in overhead costs, including what it calls "exc...
Despite Months of Private Engagement From Irenic and Presumably Other Investors, Chairman & CEO Rick E. Winningham and Theravance’s Board Refuse to Act in Shareholders’ Best Interests Notes Theravance’s Total Shareholder Returns are -50% Since Its 2014 Separat...
Summary Seth Klarman’s 13F portfolio value increased from $5.79B to $6.13B this quarter. Baupost Group increased Alphabet and Meta Platforms while dropping Dropbox and Encompass Health. The portfolio continues to be heavily concentrated with the top three positions accounting...
Theravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 PR Newswire DUBLIN , Feb. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2022 financial result...
Summary Avantax (formerly Blucora) has recently completed the sale of its tax software segment. The company subsequently announced a tender offer for 16% to 19% of outstanding shares at $27-$31/share. The stock is now trading close to the tender price range midpoint - 7% spread to t...
Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets PR Newswire Strategic priorities focused on continued Net Sales growth for YUPELRI ® (revefenacin) and conduct of the ampreloxetine Phase 3 study (CYPRESS) in Multiple System Atrophy (MS...
Theravance Biopharma, Inc. Announces Final Results of Tender Offer PR Newswire DUBLIN , Nov. 22, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the final results of its Dutch a...
Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer PR Newswire DUBLIN , Nov. 18, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the preliminary results of its ...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 PR Newswire DUBLIN , July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2024 financial results and provide a business update...
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...